valproic acid: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
valproic acid: clinical details
Prescribing considerations
- For initiation in patients aged under 55, follow current specialist-agreement and risk-acknowledgement requirements.
- For women and girls able to become pregnant, comply with Pregnancy Prevention Programme requirements, including pregnancy assessment, effective contraception, counselling and specialist review.
- Assess hepatic, metabolic, mitochondrial, pancreatic, haematological and reproductive risk factors before prescribing.
- Avoid abrupt withdrawal because of seizure recurrence or deterioration.
Contraindications and cautions
- Hypersensitivity to valproic acid or formulation excipients
- Active liver disease or a personal or family history of severe hepatic dysfunction, particularly drug-related
- Known urea-cycle disorder
- Porphyria
- Known POLG-related mitochondrial disorder, or suspected POLG-related disorder in a child under two years
- Uncorrected systemic primary carnitine deficiency
- Pregnancy or reproductive potential where product-specific specialist and Pregnancy Prevention Programme conditions are not satisfied
Monitoring
- Check liver function before treatment and periodically during the first six months, with closer surveillance in higher-risk patients.
- Obtain a full blood count including platelets and appropriate coagulation tests before treatment, before surgery and if spontaneous bruising or bleeding occurs.
- Investigate ammonia and possible carnitine deficiency if vomiting, ataxia, impaired consciousness or unexplained encephalopathy develops.
- Routine plasma-level measurement is not generally required but may assist when seizure control is poor, toxicity is suspected, adherence is uncertain or interactions are present.
Clinical pharmacology
Valproate is a broad-spectrum anticonvulsant that probably enhances inhibitory GABA activity. It is highly protein-bound, primarily metabolised by glucuronidation and has clinically important concentration-altering interactions.
Formulation and product differences
- The selected Convulex product is an enteric-coated, gastro-resistant soft capsule for oral use.
- Valproic acid, sodium valproate and semisodium valproate are related but differ in formulation, licensed indications and release characteristics; switching should be overseen by a prescriber or pharmacist.
valproic acid preparations and strengths
Capsule
Route: Oral
Strengths: 150 mg, 300 mg, 500 mg
valproic acid interactions
Valproic acid has clinically important interactions. Check prescribed, non-prescription and herbal products with a pharmacist or prescriber.
Carbapenem antibiotics, including meropenem and imipenem
They can rapidly and substantially reduce valproate concentrations, risking loss of seizure control; concurrent use should generally be avoided.
Lamotrigine
Valproate slows lamotrigine metabolism and can increase exposure and the risk of serious rash, requiring specialist management.
Warfarin and other coumarin anticoagulants
Valproate may increase anticoagulant effect and bleeding risk; closer coagulation monitoring may be needed.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.